Where does Stephen Squinto work?

Stephen Squinto is Board director at Averna Therapeutics and Board director at Gennao Bio and Board director at Enlaza Therapeutics.

What check size does Stephen Squinto write?

Stephen Squinto typically writes checks of $1M – $75M.

What boards does Stephen Squinto sit on?

Stephen Squinto holds tracked board seats at Arvinas Holding Co. LLC, Averna Therapeutics, Chemomab, Compass Therapeutics, Enlaza Therapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics, Vanqua Bio.

Where did Stephen Squinto go to school?

Stephen Squinto studied at Loyola University Chicago (Doctor of Philosophy (Ph.D.), Biochemistry).

Stephen Squinto

Investor

Board director at Averna Therapeutics · Board director at Gennao Bio · Board director at Enlaza Therapeutics · Former Executive Partner at OrbiMed

New York, New York

Writes $1M – $75M checks · typically $4M

Find your path to Stephen

333 people in our graph can introduce you to Stephen.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Elias Quijano to introduce you to Stephen

You →Elias · together at Gennao Bio (2021–2022) →Stephen

Ask Jamie Chen to introduce you to Stephen

You →Jamie · 6 people · together at Alexion Pharmaceuticals →Stephen

Ask Sam Okafor to introduce you to Stephen

You →Sam · together at J.P. Morgan Asset Management →Stephen

Your email: the people you already email who know Stephen
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Stephen
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

Stephen Squinto is Chief Investment Officer of J.P. Morgan Life Sciences Private Capital at J.P. Morgan Asset Management. He previously served as Executive Partner at OrbiMed Advisors and co-founded Alexion Pharmaceuticals, where he held roles including Executive Vice President and Chief Global Operations Officer. Dr. Squinto brings over 30 years of biotechnology experience, including senior leadership positions at Regeneron Pharmaceuticals and academic appointments at Tulane University and LSU Medical Schools, and holds a Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.

Board director at Averna Therapeutics

Intro paths

→

In turn, Stephen can intro founders to Averna Therapeutics's investors below.

Averna Therapeutics's investors · 5

ARC VENTURESNew York Deep InsightTel Aviv Delos CapitalCambridge Novartis Venture FundBasel · $5M – $25M checks · since 2024 OrbiMedNew York · $1M – $75M checks · since 2024

Board director at Gennao Bio

Intro paths

→

In turn, Stephen can intro founders to Gennao Bio's investors below.

Gennao Bio's investors · 1

OrbiMedNew York · $1M – $75M checks · since 2021

Board director at Enlaza Therapeutics

Intro paths

→

In turn, Stephen can intro founders to Enlaza Therapeutics's investors below.

Enlaza Therapeutics's investors · 8

Avalon BioVenturesLa Jolla · since 2025 Frazier Life SciencesPalo Alto · since 2025 J.P. Morgan Asset Management Lightspeed Venture PartnersMenlo Park · $1M – $5M checks OrbiMedNew York · $1M – $75M checks · since 2025 Pappas CapitalDurham Pfizer Venture Investments$5M – $20M checks Samsara BioCapitalMenlo Park · since 2025

Co-founders at Enlaza Therapeutics

Sergio DuronCo-Founder & Chief Executive Officer

Sanford MadiganCo-Founder, President & Chief Business Officer

Experience

J.P. Morgan Asset ManagementChief Investment Officer, JP Morgan Life Sciences Private Capitalcurrent2022 — presentUnited States
Gennao BioExecutive Chairman2021 — 2022
OrbiMedExecutive Partner2019 — 2022Greater New York City Area
OrbiMedVenture Partner2015 — 2019New York City Metropolitan Area
OrbiMed AdvisorsExecutive Partner2019 — 2022
Alexion Pharmaceuticals, Inc.Co-Founder; Exec VP, Head of R&D1992 — 2015
Regeneron Pharmaceuticals, Inc.Senior Leadership, Early Company Builder1988 — 1992New York

Skills & more

Life Sciences53Biotechnology58

From Stephen's professional profile.

Deals · 4

Enlaza TherapeuticsBoard seat

via OrbiMed · filed Sep 2025 · $15M raise

Compass TherapeuticsBoard seat

via OrbiMed · filed Jul 2020 · $195.3M raise

SpringWorks TherapeuticsBoard seat

via OrbiMed · filed Apr 2019 · $125M raise

Arvinas Holding Co. LLCBoard seat

via OrbiMed · filed Apr 2018 · $55M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Averna Therapeutics Chemomab Vanqua Bio

Per SEC Form D filings.

Leave your own feedback

Frequently asked questions

Who is Stephen Squinto?: Stephen Squinto is Chief Investment Officer of J.P. Morgan Life Sciences Private Capital at J.P. Morgan Asset Management. He previously served as Executive Partner at OrbiMed Advisors and co-founded Alexion Pharmaceuticals, where he held roles including Executive Vice President and Chief Global Operations Officer. Dr. Squinto brings over 30 years of biotechnology experience, including senior leadership positions at Regeneron Pharmaceuticals and academic appointments at Tulane University and LSU Medical Schools, and holds a Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.
Where does Stephen Squinto work?: Stephen Squinto is Board director at Averna Therapeutics and Board director at Gennao Bio and Board director at Enlaza Therapeutics.
What check size does Stephen Squinto write?: Stephen Squinto typically writes checks of $1M – $75M.
What boards does Stephen Squinto sit on?: Stephen Squinto holds tracked board seats at Arvinas Holding Co. LLC, Averna Therapeutics, Chemomab, Compass Therapeutics, Enlaza Therapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics, Vanqua Bio.
Where did Stephen Squinto go to school?: Stephen Squinto studied at Loyola University Chicago (Doctor of Philosophy (Ph.D.), Biochemistry).